Business Context and Reporting Period
This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. on March 20, 2025. The filing discloses the execution of a new employment agreement for a senior executive officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes
The primary material change reported is the transition of Tony Goodman from a contractor to a direct employee:
- Role: Chief Operating Officer (COO).
- Effective Date: April 1, 2025.
- Previous Arrangement: Mr. Goodman served as COO since January 2024 under a Master Services Agreement with The Keswick Group, LLC. This contractor relationship terminates on the Effective Date.
- Compensation Structure:
- Annual Base Salary: $300,000.
- Discretionary Bonus: Up to 30% of base salary based on objectives determined by the Board.
- Severance: 6 months for without-cause termination; 12 months for without-cause termination following a change of control.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of operational risks. It notes that there are no family relationships between Mr. Goodman and the Company's directors or officers, and no other transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the full text of the Goodman Employment Agreement attached as Exhibit 10.1 for specific performance metrics tied to the discretionary bonus.
- Confirm the termination date of the Master Services Agreement with The Keswick Group, LLC to ensure no overlapping liabilities.
- Review the Company's cash position in the most recent 10-Q or 10-K to assess the impact of the new $300,000 annual salary obligation on liquidity.